Novartis Ag (NVS) Long-Term Investments (2009 - 2026)
Novartis Ag (NVS) posted Long-Term Investments of $2.3 billion for Q2 2026, up 2202.0% sequentially from $100.0 million in Q1 2026, and up 2402.17% YoY from $92.0 million in Q2 2025.
Novartis Ag (NVS) Long-Term Investments (2009 - 2026) Analysis & Trends
Novartis Ag has reported Long-Term Investments for 18 years, with the latest figure at $2.3 billion in Q2 2026.
- Quarterly Long-Term Investments rose 2402.17% year-over-year to $2.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.3 billion (up 2402.17% YoY) and the FY2025 annual result came in at $2.3 billion, up 1873.11% from the prior year.
- Long-Term Investments rose to $2.3 billion in Q2 2026 per NVS's latest filing, from $100.0 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $2.3 billion in Q4 2025 and troughed at -$106.0 million in Q4 2023.
- A 5-year average of $349.7 million and a median of $116.5 million in 2024 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2023 and 2026: Long-Term Investments sank 265.52% in 2023, then soared 2402.17% in 2026.
- Over 5 years, Long-Term Investments stood at -$29.0 million in 2022, then tumbled by 265.52% to -$106.0 million in 2023, then jumped by 212.26% to $119.0 million in 2024, then jumped by 1873.11% to $2.3 billion in 2025, then slipped by 1.96% to $2.3 billion in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $2.3 billion, $100.0 million, and $2.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 266.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.22 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 69.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 297.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1.56 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 135.51 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 3.73 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.30 Bn |
| Mar 31, 2026 | 100.00 Mn |
| Dec 31, 2025 | 2.35 Bn |
| Sep 30, 2025 | 85.00 Mn |
| Jun 30, 2025 | 92.00 Mn |
| Mar 31, 2025 | 114.00 Mn |
| Dec 31, 2024 | 119.00 Mn |
| Sep 30, 2024 | 106.00 Mn |
| Jun 30, 2024 | 103.00 Mn |
| Mar 31, 2024 | 95.00 Mn |
| Dec 31, 2023 | -106.00 Mn |
| Sep 30, 2023 | 202.00 Mn |
| Jun 30, 2023 | 127.00 Mn |
| Mar 31, 2023 | 130.00 Mn |
| Dec 31, 2022 | -29.00 Mn |
| Sep 30, 2022 | 144.00 Mn |
| Jun 30, 2022 | 167.00 Mn |
| Mar 31, 2022 | 195.00 Mn |
| Dec 31, 2021 | 3.04 Bn |
| Sep 30, 2021 | -46.00 Mn |